These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34763450)

  • 21. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure.
    Vaduganathan M; Greene SJ; Zhang S; Solomon N; Chiswell K; Devore AD; Butler J; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Mcdermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Fonarow GC
    J Card Fail; 2022 Apr; 28(4):554-563. PubMed ID: 34785402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.
    Papademetriou V; Geladari E
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):127-133. PubMed ID: 29618313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Sodium-Glucose Cotransporter-2 Inhibitors and Thiazolidinedione on New-Onset Atrial Fibrillation Risk to Patients with Type 2 Diabetes.
    Song H; Kim YR; Lee SE; Nam H; Kim H; Kyoung DS; Kim KA
    Rev Cardiovasc Med; 2022 Sep; 23(9):303. PubMed ID: 39077692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events.
    Aziri B; Begic E; Jankovic S; Mladenovic Z; Stanetic B; Kovacevic-Preradovic T; Iglica A; Mujakovic A
    ESC Heart Fail; 2023 Jun; 10(3):1499-1530. PubMed ID: 36967133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
    Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
    Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
    Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
    Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME; Kosiborod M
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
    Cavender MA; Norhammar A; Birkeland KI; Jørgensen ME; Wilding JP; Khunti K; Fu AZ; Bodegård J; Blak BT; Wittbrodt E; Thuresson M; Fenici P; Hammar N; Kosiborod M;
    J Am Coll Cardiol; 2018 Jun; 71(22):2497-2506. PubMed ID: 29852973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
    Al Rifai M; Newby LK; Nair AP; Misra A; Rogers JG; Fedson S; Virani SS
    Curr Atheroscler Rep; 2022 Aug; 24(8):627-634. PubMed ID: 35653033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions.
    Fauchier L; Bisson A; Bodin A
    BMC Med; 2023 Feb; 21(1):54. PubMed ID: 36782248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis.
    Ong HT; Teo YH; Teo YN; Syn NL; Wee CF; Leong S; Yip ASY; See RM; Ting AZH; Chia AZ; Cheong AJY; Tan BY; Ho JS; Yeo LL; Leow AS; Yeo TC; Wong RC; Chai P; Kojodjojo P; Sia CH
    J Stroke Cerebrovasc Dis; 2022 Jan; 31(1):106159. PubMed ID: 34689051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis.
    Fukuta H; Hagiwara H; Kamiya T
    Medicine (Baltimore); 2021 Dec; 100(51):e28448. PubMed ID: 34941199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis.
    Zhao L; Guo W; Huang W; Wang L; Huang S
    Diabetes Res Clin Pract; 2022 May; 187():109871. PubMed ID: 35413392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 39. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure.
    Sharma A; Ezekowitz JA
    Can J Diabetes; 2020 Feb; 44(1):103-110. PubMed ID: 31630988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.